. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Biochem Pharmacol. 2019 Mar 15;167:149–162. doi: 10.1016/j.bcp.2019.03.021

Table 1.

The effect of 5F02, olaparib, and enzalutamide on the viability of LNCaP expressing both wild-type and constitutively active AR splice variant AR-V7. Cell viability was examined using the CellTiter Blue assay. The effective doses (ED) were calculated using XLfit software.

5F02				Olaparib				Enzalutamide
ED₉₀ μM	ED₇₀ μM	ED₅₀ μM	ED₂₀ μM	ED₉₀ μM	ED₇₀ μM	ED₅₀ μM	ED₂₀ μM	ED₉₀ μM	ED₇₀ μM	ED₅₀ μM	ED₂₀ μM
15.7	8.9	6.3	3.5	1835	228.7	61.9	7.3	4751.7	163.7	19.8	0.6